Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature

Expert Opinion on Drug Metabolism & Toxicology(2023)

引用 0|浏览0
ABSTRACTIntroduction Drug absorption is often altered and typically diminished in patients with short bowel syndrome (SBS). It is important to understand the patient’s gastrointestinal anatomy, the absorptive capacity of the remaining bowel, and the physicochemical and pharmacokinetic properties of the drug to optimize oral pharmacotherapy.Areas covered The primary focus was to provide an updated understanding of the absorption of various drugs in patients with short bowel syndrome. Forty-seven studies covering 13 different drug classes were included in the review and study details, patient characteristics, drug characteristics and pharmacokinetic findings were summarized for each drug class.Expert opinion Improving and simplifying drug treatment in patients with SBS have high priority, but the patients are multi diseased so knowledge regarding absorption of drugs as e.g. antithrombotic agents, immunosuppressants is urgently needed. Therefore, it is crucial to advance our understanding of the fundamental factors involved in drug absorption, spanning from drug design to pathophysiology. With the growing knowledge in drug design and gastrointestinal pathophysiology, we anticipate the development of computer models that can accurately predict optimal absorption in the future.KEYWORDS: Bioavailabilitydrug absorptionintestinal failurepharmacokineticshort bowel syndrome Article highlights Drug absorption from oral administration is often altered and typically diminished in patients with short bowel syndrome.Fortyseven studies have investigated drug absorption from oral administration in patients with short bowel syndrome.Some drug classes are sufficiently absorbed, others are not.For some drug classes length of the remaining intestine and colon continuity impact drug absorption.Declaration of interestThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis paper was not funded.
short bowel syndrome,oral formulations,absorption,drug
AI 理解论文
Chat Paper